Comparison of Behçet's Disease and Recurrent Aphthous Ulcer According to Characteristics of Gastrointestinal Symptoms by Rhee, Seung-Ho et al.
INTRODUCTION
Behcet’s disease (BD) is a multisystemic, chronic, relapsing
vasculitis that affects nearly all organs and systems. The gas-
trointestinal (GI) tract is not infrequently involved in patients
with BD. The frequency of GI involvement varies in different
countries: there are several studies, mostly from Japan, report-
ing a high frequency (50-60%) of GI involvement in BD (1),
while a significant lower rate, less than 5%, is seen in Turkish
patients (2). GI involvement has been reported in 8% of pa-
tients in the United States (3). Any portion of the GI tract may
be involved. The upper GI tract is less frequently affected, but
ulcerations in the esophagus and stomach have been reported.
These patients commonly present with symptoms of hemate-
mesis, melena, and epigastric pain. The terminal ileum, cecum,
and ascending colon are the sites most frequently affected, re-
sulting in abdominal pain, diarrhea, and hematemesis.
Recurrent aphthous ulcer (RAU) represent a very common
but poorly understood mucosal disorder. They occur in men
and women of all ages, races and geographic regions. It is esti-
mated that at least 1 in 5 individuals has at least once been
afflicted with aphthous ulcers (4). The condition is classified
as minor, major, and herpetiform on the basis of ulcer size and
number. Attacks may be precipitated by local trauma, stress,
food intake, drugs, hormonal changes and vitamin and trace
element deficiencies (4). Local and systemic conditions, and
genetic, immunological and microbial factors all may play a
role in the pathogenesis of recurrent aphthous ulceration. How-
ever, to date, no principal cause has been discovered. Since the
etiology is unknown, diagnosis is entirely based on history
and clinical criteria and no laboratory procedures exist to con-
firm the diagnosis. Although RAU may be a marker of an un-
derlying systemic illness such as celiac disease, or may present
as one of the features of BD, in most cases no additional body
systems are affected, and patients otherwise remain fit and
well. 
We often see patients of RAU with GI symptoms without
any other symptoms of BD on out-patient clinic. In many
cases it is difficult to distinguish intestinal BD from RAU
with gastrointestinal symptom. Because the pathognomonic
clinical features and tools are absent, the diagnosis of these
two diseases relies on the characteristic clinical features and
the judgement of the experienced physician.
The aim of this study is to help the differential diagnosis
of intestinal BD and RAU with gastrointestinal symptoms
through the comparison of clinical, endoscopic, histopatho-
logic, and serologic findings.
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Comparison of Behcet’ s Disease and Recurrent Aphthous Ulcer
According to Characteristics of Gastrointestinal Symptoms
Behcet’s disease (BD) is a multisystemic chronic inflammatory disease. It is charac-
terized by recurrent oral and genital ulcers, uveitis, skin lesions and other manifesta-
tions, including neurologic, vascular, joint, and gastrointestinal ulcers of variable severi-
ty. Recurrent aphthous ulcer (RAU) represents a very common, but poorly under-
stood, mucosal disorder. If a patient of RAU without any other typical symptoms of
BD has gastrointestinal symptoms, it is difficult to distinguish this RAU from true BD
with gastrointestinal involvement. Because pathognomonic clinical features and tools
are absent, the differential diagnosis of these two diseases relies on the character-
istic clinical features and the judgement of an experienced physician. Sixty-five out
of a total 960 RAU patients and forty-four of 556 BD patients with gastrointestinal
symptoms between January 1996 and December 2003 participated in this study. All
were evaluated with esophagogastroduodenoscopy and colonoscopy. Clinical, endo-
scopic and histopathologic findings were analyzed and ELISA tests were conduct-
ed to detect serum levels of ASCA and pANCA. No significant difference was found
between the two groups. Differential diagnosis between RAU with gastrointestinal
symptoms and BD with gastrointestinal involvement requires further prospective,
large-scale study.
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MATERIALS AND METHODS
Patients 
Sixty five of total 960 RAU patients and 44 of total 556
BD patients who visited the Depatment of Dermatology of
Ajou University School of Medicine, Suwon, Korea, between
January 1996 and December 2003 were invited to participate
in this study and all of the patients had GI symptoms and
were evaluated with esophagoduodenoscopy and colonoscopy.
Sera were obtained from 12 patients with RAU, 16 patients
with BD, and 4 healthy volunteers. 
Clinical and endoscopic findings
The clinical records of these patients were reviewed. BD
was diagnosed according to the Japanese diagnostic criteria
for BD revised in 1987. Our study was based on BD patients
with gastrointestinal symptoms and recurrent oral ulceration.
We found out that RAU patients had no other symptom of
BD. Contents reviewed were age, sex, age of onset, first mani-
festation, gastrointesinal symptoms, other symptoms of BD.
We investigated the endoscopic findings with respect to
location, distribution, and morphology of the ulceration.
Histopathologic findings
A part of each specimen was fixed in 10% buffered neutral
formalin and was embedded in paraffin. Sections were deparaf-
finized and rehydrated by sequential immersion in xylene, gra-
ded concentration of ethanol, and distilled water. Hematoxy-
lin-eosin stain was done to observe the general histological
changes.
We investigated all specimens with respect to presence of
vasculitis and granuloma, infiltration type, dominant cell type
and crypt architecture.
Serologic findings (ASCA and pANCA)
Serum was obtained from 12 patients with RAU, 12 pa-
tients with BD, and 4 healthy volunteers. Each serum was
collected in a sterile tube with EDTA coating. The test tubes
were centrifuged at 4℃, 3,000 rpm for 5 min. The serum
was kept at -20℃until the assay. 
ASCA immunoglobin G (IgG) was evaluated by a commer-
cially available enzyme-linked immunosorbent assay (ELISA)
kit (Inova Diagnostics, San Diego, CA, U.S.A.). ASCA ELISA
was performed according to the manufacturer’s manuals. The
antigen consisted of phosphopeptidomannan extracted from
Saccharomyces cerevisiae. All sera were tested in duplicate. Re-
sults were expressed as arbitrary units with a cut-off for pos-
itivity of 25 U/mL.
The ANCA indirect immunofluorescence assay was perfor-
med according to the following method. In short, human peri-
pheral blood neutrophils were smeared on 12-well Nutacon
slides (Nutacon BV, Leimuiden, the Netherlands) and fixed
in 96% ethanol (10 min at -20℃). Slides were incubated with
1:20 diluted patient’s serum (in phosphate buffered saline) and
stained with rabbit anti-human IgG-fluorescein isothiocya-
nate (FITC) conjugate (Dako A/S, Glostrup, Denmark). The
slides were evaluated by fluorescence microscopy. All sera were
tested in duplicate and scored by two well-trained observers
who were unaware of the patients’ diagnoses. Depending on
the brightness of the immunofluorescence staining pattern,
the reactions were graded either negative (-) or positive (+). 
Statistics
Statistical analysis was done by Wilcoxon rank sum test and
logistic regression. A p value of less than 0.05 was considered
as statistically significant.
RESULTS 
Clinical and endoscopic findings
There were no significant differences in clinical findings
between patients with RAU and BD by statistical analysis.
Oral lesion was the most common first manifestation of BD
patients. Abdominal pain was the most common gastroin-
testinal symptom of both groups (Table 1, 2).
There were no significant differences in endoscopic charac-
teristics between patients with RAU and BD (Table 3). On
esophagoduodenoscopy, ulcerations were observed in 20% of
RAU and 16% of BD. On colonoscopy, ulceration were ob-
served in 47% of  RAU and 65% of BD. Ileocecal region was
most common ulceration site of both two groups. 
There were no statistical differences in ulcer characteristic
between patients with RAU and BD (Table 4). But two cases
of BD had ulcer perforation.
Histopathologic findings
Most common histopathologic findings of RAU and BD
RAU, recurrent aphthous ulcer; BD, Behcet’s disease; NS, not significant.
RAU (n=65) BD (n=44) p value
Mean age (yr; mean (range)) NS
Male 40.3 (15-69) 38.4 (18-57)




Age of onset (yr; mean (range)) NS
Male 37.8 (10-61) 30.3 (8-50)
Female 31.6 (13-65) 28.5 (12-45)
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were vasculitis, patch mixed lymphocyte dominant infiltra-
tion (Table 5). There were no statistical differences between
patients with RAU and BD.
Serologic findings
Only one patient (6%) with intestinal BD and one patient
(8%) with RAU were IgG ASCA positive. Median level of
ASCA was highest in serum of patient with BD (Fig 1). And
one patient with intestinal BD was pANCA positive. How-
ever, there were no statistical differences between patients with
intestinal BD, RAU and healthy volunteers (Table 6).
DISCUSSION
The clinical diagnosis of BD may pose considerable difficul-
ties. Since the disease is multi-systemic and does not have any
pathognomonic symptom or laboratory findings, the diagno-
sis is based on a cluster of clinical manifestations. Thus, the
presence of a relatively specific laboratory marker can substan-
RAU, recurrent aphthous ulcer; BD, Behcet’s disease; NS, not significant.
*A patient may have multiple esophagogastroduodenoscopy or colonos-
copy findings.
RAU (%)  BD (%) 
p value
(n=65) (n=44)
Esophagogastroduodenoscopy* 55 30 NS
Normal 3 (5) 0 (0)
Esophageal ulcer 5 (9) 4 (13)
Gastritis 45 (82) 27 (90)
Gastric ulcer 1 (2) 0 (0)
Duodenal ulcer 5 (9) 1 (3)
Gastric polyp 2 (4) 0 (0)
Gastric cancer 2 (4) 0 (0)
Colonoscopy* 17 20 NS
Normal 8 (47) 9 (45)
Ulcer 8 (47) 13 (65)
Ileocecal region 6 11
Ascending colon 1 1
Transverse colon 0 0
Descending colon 0 0
Sigmoid colon 0 0
Rectum 1 1
Colonic polyp 2 (12) 2 (10)
Table 3. Endoscopic characteristic of patients with RAU and BD
RAU, recurrent aphthous ulcer; BD, Behcet’s disease; NS, not significant.
RAU (%) (n=19) BD (%) (n=18) p value
Number NS
Single 11 (58) 10 (56)
Multiple 8 (42) 8 (44)
Shape NS
Geographic 3 (16) 2 (11)
Longitudinal 0 (0) 0 (0)
Round 8 (42) 7 (39)
Aphthous 8 (42) 9 (50)
Margin NS
Punched out 11 (58) 12 (66)
Elevated 8 (42) 6 (34)
Perforation 0 (0) 2 (11)
Table 4. Ulcer characteristic of patients with RAU and BD
RAU, recurrent aphthous ulcer; BD, Behcet’s disease; NS, not significant.
RAU (%) (n=12) BD (%) (n=10) p value
Histopathology NS
Vasculitis 6 (50) 7 (70)
Granuloma 0 (0) 0 (0)
Lymphoid aggregation 6 (50) 3 (30)
Infiltration type NS
Patched, mixed 6 (50) 8 (80)
Diffuse, mixed 3 (25) 2 (20)
Mild, mixed 3 (25) 0 (0)
Dominant cell NS
Lymphocyte 12 (100) 9 (90)
Plasma cell 0 (0) 1 (10)
Crypt architecture NS
Intact 12 (100) 8 (80)
Damaged 0 (0) 2 (20)
Table 5. Histopathologic characteristic of patients with RAU and
BD
RAU, recurrent aphthous ulcer; BD, Behcet’s disease; NS, not significant.
RAU (n=65) BD (n=44) p value
First manifestation (%)
Oral lesion 65 (100) 39 (88)
Genital lesion - 2 (5)
Skin lesion - 3 (7)
Ocular lesion - 0 (0)
BD subclass (%)
Complete - 2 (5)
Incomplete - 19 (43)
Suspected - 23 (52)
Major symptom (%)
Oral lesion 65 (100) 44 (100)
Genital lesion - 38 (86)
Skin lesion - 20 (45)
Ocular lesion - 5 (11)
Positive pathergy test (%) - 2 (5)
Minor symptom (%)
Joint manifestation - 19 (43)
Epididymitis - 0 (0)
Vascular manifestation - 0 (0)
Central nervous system symptom - 3 (7)
Gastrointestinal symptom (%) NS
Abdominal pain 35 (54) 29 (66)
Indigestion 21 (32) 10 (23)
Diarrhea 13 (20) 13 (30)
Melena/Hematochezia 5 (8) 5 (11)
Nausea 5 (8) 4 (9)
Vomiting 2 (3) 2 (5)
Constipation 1 (2) 1 (2)
Weight loss 0 (0) 0 (0)
Table 2. Clinical characteristic of patients with RAU and BD974 S.-H. Rhee, Y.-B. Kim, E.-S. Lee
tially facilitate the diagnosis of BD, and possibly support a
diagnosis before all disease manifestations have occurred.
RAU is seen in most patients with BD; it commonly pre-
cedes other systemic features. However, it is difficult to pre-
dict with certainty those patients initially presenting with
RAU who will subsequently proceed to develop multisystem
involvement as part of BD. A clinical comparison between
38 patients with BD and RAU-only controls showed an in-
creased number of concurrent ulcers and involvement of the
soft palate and oropharynx in those diagnosed with BD (5).
No differences were detected with respect to duration, fre-
quency, age of onset or family history. The aphthae in BD often
occur in the soft palate and oropharynx and have been obser-
ved on the hard palate, which is an unusual site for RAU in
patients without BD (5). Bang et al. examined the prognosis
of the clinical relevance of recurrent oral ulceration in BD, and
the investigators found that approximately half the patients
who were initially diagnosed as RAU-only, developed other
manifestations of BD in an average of 7.7 yr after onset (6).
They reported that highly recurrent RAU had appeared to be
a warning signal for BD.
Many authors consider the onset to be the age at which the
patient fulfilled the diagnostic criteria. The third decade is the
most commonly reported age of onset for BD, and the fourth
decade for intestinal BD (7). In our study, intestinal BD occu-
rred at a mean age of 29.0 yr and RAU occurred at a mean
age of 34.7 yr. Although the mean age of RAU was higher
than BD, no difference was found between the two groups in
statistical analysis.
The male to female ratio in BD also differs geographically
(1); however, the gender ratio in terms of intestinal BD has
not been well characterized in Mediterranean and Western
countries, probably because of its relative rarity. The male to
female ratio of BD in this study (0.57:1) was incompatible
with the reported ratio in Korea (0.7-1.3:1) (8) and Japan (1.7:
1) (7). But there were no significant differences with BD and
RAU (0.8:1).
It has been well known for many years that BD is often
accompanied by such gastrointestinal symptoms as nausea,
vomiting, and abdominal pain (9). About 22 percent of pa-
tients with intestinal BD developed appendicitis-like symp-
toms during the clinical course (10). Our study showed that
the most common presenting symptom in intestinal BD and
RAU with GI symptoms is abdominal pain (66% and 54%).
Diarrhea and indigestion were the next common presenting
symptoms in these two groups.
The pathologic hallmark of intestinal BD is known to be
the presence of a few punched-out ulcers of variable size and
appearance (11). The smaller ulcers (“aphthoid ulcers”) have
been considered histologically to be similar to the oral apht-
hous ulcers of BD (12). Larger ulcers usually have an oval or
irregular configuration. The depth of penetration of the ulcers
varies. Superficial ulcers occasionally have been shown to re-
solve (13), but deeper ulcers, often with a narrow fissuring
appearance, can extend through the bowel wall. Intestinal per-
foration is, therefore, a common complication (14). Progno-
sis of intestinal BD is worse than other inflammatory bowel
disease, which is due to high perforation rate in intestinal BD
(15). Although intestinal BD is diagnosed radiologically or
endoscopically in many cases, relatively few descriptions about
the endoscopic characteristics of intestinal BD exist in liter-
ature. Morphological characteristics of intestinal BD have
been reported to be discrete ulcerations that have a confluent
and discrete border, appearing most commonly in the ileoce-
cal region (9, 14). 
In our series, most of the ulcers in intestinal BD and RAU
on colonoscopy were found in the ileocecal areas, but they may
be present at any site throughout the digestive system. Many
of the patients had single or relatively few ulcers with locali-
zed distribution. The colonoscopic characteristics of intesti-
nal BD could be summarized as large sized, round/oval or
geographically shaped, deep and discrete ulcer with elevated
RAU, recurrent aphthous ulcer; BD, Behcet’s disease; ASCA, Anti-Sac-
charomyces cerevisiae mannan antibody; pANCA, perinuclear antineu-
trophil cytoplasmic autoantibody; NS, not significant.
RAU (%)  BD (%)  Healthy control 
p value
(n=12) (n=16) (%) (n=4)
ASCA NS
Positive 1 (8) 1 (6) 0 (0)
Negative 11 (92) 14 (88) 4 (100)
Equivocal 0 (0) 1 (6) 0 (0)
pANCA NS
Positive 0 (0) 1 (6) 0 (0)
Negative 12 (100) 15 (94) 4 (100)
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Fig.1. ASCA levels in patients with recurrent aphthous ulcer (RAU),
Behcet’s disease (BD), and healthy controls. Levels equal to or




5.5margins. Because we only have examined the endoscopy pho-
tographs, it was difficult to find the differences in ulcer shape,
location and distribution pattern between intestinal BD and
RAU.
Lee et al. classified BD patients into typical (complete and
incomplete) and atypical (suspected and possible) group. And
after comparing the clinical and colonoscopic characteristics
of the two groups, concluded that there was no significant di-
fference between the two groups and that a “suspected or pos-
sible” type could be included in the BD category if an intesti-
nal involvement was identified (16). Since over half of the
patients in our study were diagnosed as BD suspected type,
there may not have been a significant difference with the RAU
group.
The ulcers from the intestinal BD tend to be deep and pe-
netrating and, thus, frequently require surgical interventions
(17, 18). Complications of GI ulceration in BD may include
perforation and enterocutaneous fistula. Surgical treatment
is often necessary, but postoperative recurrence is as high as
68% (8). In the current study, we found that two cases of in-
testinal BD recurred after operation. Therefore, more atten-
tion should be paid in patients with perforating type of in-
testinal BD.
The intestinal ulcer of BD is characterized not only by ab-
sence of the granulomatous formation of Crohn’s disease, but
also by deeper penetration of ulcer to regions nearer the serous
membrane than the ulcers of ulcerative colitis. But these cha-
racteristics are not helpful in the diagnosis of BD. Histologi-
cally, Behcet’s ulcers contain nonspecific chronic inflamma-
tion. A nonnecrotizing lymphocytic vasculitis affects small
veins and venules without thrombosis (19). But still it is nec-
essary to carefully examine the clinical symptoms and signs
and the histopathological appearance, since in many cases the
differential diagnosis is very difficult.
In our study, most common histopathologic findings of
intestinal ulcers in BD were vasculitis, patched mixed lym-
phocyte dominant infiltration. There were no significant dif-
ferences between patients with intestinal BD and RAU.
Since 1990, perinuclear anti-neutrophil cytoplasmatic anti-
bodies (pANCAs), which show a specific staining on indirect
immunofluorescence, have been consistently found in 40-80%
of patients suffering from ulcerative colitis (20, 21). They are
spontaneously produced by lamina propria and mesenteric
node lymphocytes (21). In ulcerative colitis, the antigen rec-
ognized by pANCAs is located in the inner side of the nucle-
ar periphery and is DNase sensitive, but the exact epitope re-
mains yet unknown. It is hypothesized that the pANCAs are
due to cross-reactivity with bacterial antigens (22, 23) 
Antibodies to baker’s yeast and brewer’s yeast (ASCA) have
been described in up to 65% of patients with Crohn’s disease
(24, 25). It has been demonstrated that the specific antigen
is a mannan localized in the yeast cell wall (25). The signifi-
cance of ASCAs in Crohn’s disease is completely unknown,
but one hypothesis links them to increased intestinal perme-
ability (26). Due to this presumed break in the epithelial bar-
rier, increased exposure of the epithelium to common food
antigens such as yeasts may result in an exaggerated antibody
response.
Kim et al. have reported that ASCA may be associated with
Crohn’s disease and BD and pANCA with ulcerative colitis.
A result that is ASCA positive and pANCA negative was asso-
ciated with Crohn’s disease and BD, whereas a positive pANCA
in combination with a negative ASCA result was strongly cor-
related with ulcerative colitis. A combination of both tests may
aid the differential diagnosis of inflammatory bowel disease
(27). Recently, Krause et al. have reported significantly higher
ASCA values in BD patients compared with patients with
RAU, SLE or healthy volunteers. This implies that ASCA,
taken in appropriate clinical context, could become a useful
diagnostic tool for BD (28). Also, they have reported ASCA
titers were significantly higher in BD patients companied to
their healthy family members. ASCA seem to be strongly
related to BD expression and are not associated with environ-
mental or genetic factors.
Unlike previous reports in our study, ASCA and pANCA
levels were not different between the two groups. The medi-
an value of ASCA level was higher in BD but this finding was
not statistically significant. There were neither clinical, endo-
scopical, histopathological nor serological differences between
patients with intestinal BD, RAU and healthy volunteers in
ASCA and pANCA. Further prospective studies with a larger
number of patients are needed to make a diagnosis tool of in-
testinal BD and RAU. 
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